New study aims to unlock secrets of prostate cancer treatment resistance
NCT ID NCT07154914
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will follow 396 men with metastatic hormone-sensitive prostate cancer to understand how the disease changes over time and becomes resistant to therapy. Participants receive standard treatments like abiraterone plus hormone therapy, and researchers will analyze genetic differences to see which combinations work best. The goal is to improve personalized treatment for advanced prostate cancer.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Abiraterone plus androgen deprivation therapy (ADT)
- What this could lead to
- If successful, this study could help doctors choose the most effective treatment combinations for men with advanced prostate cancer based on their genetic profile.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test new therapies. Results may not apply to all patients or lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 396 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2025
An estimate. Start dates often move.
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Male patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), recruited from multiple centers in China. Eligible patients are treatment-naïve and will receive androgen deprivation therapy (ADT) combined with different regimens according to real-world clinical practice.
- Ages
-
18 to 85 years
- Sex
-
Male participants only
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male patients, age \>18 and \<85 years. 2. Histologically confirmed prostate adenocarcinoma, ductal adenocarcinoma, or intraductal carcinoma. 3. Evidence of distant metastases by imaging (according to RECIST criteria). 4. No prior systemic therapy for prostate cancer (no ADT or other systemic treatments). 5. ECOG performance status 0-2 and estimated life expectancy \>6 months. 6. Adequate organ function as indicated by: * Hemoglobin ≥ 90 g/L * ANC ≥ 1.5 × 10\^9/L * Platelet count ≥ 75 × 10\^9/L * WBC ≥ 3 × 10\^9/L ⑤ Total bilirubin ≤ ULN ⑥ ALT/AST ≤ 2.5 × ULN ⑦ Creatinine clearance ≥ 30 mL/min (Cockcroft-Gault formula) * INR ≤ 1.5 or PT \< 4 sec above ULN 7. Ability to provide written informed consent. Exclusion Criteria: 1. Histological diagnosis of neuroendocrine or small-cell prostate cancer. 2. No evidence of distant metastases on imaging. 3. Prior systemic therapy for prostate cancer (neoadjuvant, adjuvant, or systemic). 4. Severe endocrine, metabolic, gastrointestinal, hepatic, or renal disease (including chronic hepatitis, cirrhosis, chronic nephritis, or renal failure). 5. History of immunodeficiency, including HIV positivity, congenital immunodeficiency, or organ transplantation. 6. History of other malignancies (except non-melanoma skin cancer). 7. Concurrent participation in another clinical trial. 8. Inability to provide clinical information or anticipated loss to follow-up. 9. Any condition deemed unsuitable for study participation by the investigator.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic hormone-sensitive prostate cance are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.